MX2020005557A - Agonistas de fxr para el tratamiento de enfermedades hepaticas. - Google Patents

Agonistas de fxr para el tratamiento de enfermedades hepaticas.

Info

Publication number
MX2020005557A
MX2020005557A MX2020005557A MX2020005557A MX2020005557A MX 2020005557 A MX2020005557 A MX 2020005557A MX 2020005557 A MX2020005557 A MX 2020005557A MX 2020005557 A MX2020005557 A MX 2020005557A MX 2020005557 A MX2020005557 A MX 2020005557A
Authority
MX
Mexico
Prior art keywords
liver diseases
treatment
fxr agonists
fxr
agonists
Prior art date
Application number
MX2020005557A
Other languages
English (en)
Inventor
Michael Badman
Bryan Laffitte
Clifford Brass
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020005557A publication Critical patent/MX2020005557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

La invención proporciona métodos para modular la actividad de los receptores farnesoides X (FXR) usando dosis específicas de tropifexor, en particular para tratar o prevenir enfermedades hepáticas.
MX2020005557A 2017-11-30 2018-11-28 Agonistas de fxr para el tratamiento de enfermedades hepaticas. MX2020005557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593084P 2017-11-30 2017-11-30
PCT/IB2018/059383 WO2019106550A1 (en) 2017-11-30 2018-11-28 Fxr agonists for the treatment of liver diseases

Publications (1)

Publication Number Publication Date
MX2020005557A true MX2020005557A (es) 2020-08-20

Family

ID=64959384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005557A MX2020005557A (es) 2017-11-30 2018-11-28 Agonistas de fxr para el tratamiento de enfermedades hepaticas.

Country Status (12)

Country Link
US (2) US20190161483A1 (es)
EP (1) EP3716977A1 (es)
JP (1) JP2021504370A (es)
KR (1) KR20200094175A (es)
CN (1) CN111356458A (es)
AU (1) AU2018376904B2 (es)
CA (1) CA3081656A1 (es)
IL (1) IL274747A (es)
MX (1) MX2020005557A (es)
RU (1) RU2020121222A (es)
TW (1) TW201936189A (es)
WO (1) WO2019106550A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014349A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2712617B2 (en) * 2004-03-12 2020-11-18 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using Fxr ligands
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP6941109B2 (ja) * 2016-02-22 2021-09-29 ノバルティス アーゲー Ｆｘｒアゴニストを使用するための方法
AU2017223148B2 (en) * 2016-02-22 2019-07-18 Novartis Ag Methods for using FXR agonists
SI3419625T1 (sl) * 2016-02-22 2021-08-31 Novartis Ag Postopki za uporabo agonistov FXR

Also Published As

Publication number Publication date
RU2020121222A3 (es) 2022-04-19
AU2018376904B2 (en) 2021-07-22
TW201936189A (zh) 2019-09-16
RU2020121222A (ru) 2021-12-30
IL274747A (en) 2020-07-30
CN111356458A (zh) 2020-06-30
JP2021504370A (ja) 2021-02-15
AU2018376904A1 (en) 2020-05-21
CA3081656A1 (en) 2019-06-06
US20210361638A1 (en) 2021-11-25
EP3716977A1 (en) 2020-10-07
US20190161483A1 (en) 2019-05-30
WO2019106550A1 (en) 2019-06-06
KR20200094175A (ko) 2020-08-06

Similar Documents

Publication Publication Date Title
PH12018501656A1 (en) Methods for using fxr agonists
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
GB2541571A (en) Pharmaceutical compositions
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
PH12019500326A1 (en) Combination of fxr agonists
PH12017500275A1 (en) Methods of treating depression using nmda modulators
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2018003301A (es) Inhibidores de pcna.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2021006102A (es) Suministro mejorado de agentes grandes.